Enclosures
Page 1 of 1
Bonn/Brussels, 10 September 2020
Dear Ministers,
The COVID-19-pandemic is inflicting huge human and economic costs on the Euro-
pean Union (EU) and the world. As you know, a permanent solution to this crisis is most
likely to be brought about by the development and deployment of an effective and safe vac-
cine against the virus.
The scale of the crisis means that time pressure is unprecedented. We have to invest
up-front in vaccine development to ensure that successful and safe vaccines are being pro-
duced at the scale required as early as possible. This is why the Commission adopted an
EU Strategy for COVID-19 vaccines and decided to finance a part of the upfront costs faced
by vaccines producers from the Emergency Support Instrument (“ESI”).
You have all endorsed this Strategy, and this swift and unified action by the European
Commission representing the EU Member States will ensure sufficient and quick delivery of a
safe and effective vaccine.
In order to maximise the chances of success, the most promising candidates should be
supported in their development and in the building-up of manufacturing capacity.
Our common goal is to obtain a broad portfolio of vaccine candidates that contain dif-
ferent technological approaches to achieve the highest possible chances of a successful vac-
cine against COVID-19.
During the virtual meeting of EU Health Ministers on 4 September 2020, a large ma-
jority of you supported the idea of a broad portfolio, which would improve our chances of
having access to a safe and effective vaccine as soon as possible.
Page 2 of 2 As you all know, exploratory talks have been concluded with six manufacturers of po-
tential vaccines and the first Advanced Purchase Agreement (APA) has been already signed
with AstraZeneca, securing our access to what will probably be the first vaccine against
COVID-19. In addition, negotiations are currently underway with other manufacturers.
However, for the next steps funding has become a key issue, as the availability of funds from
the EU Budget within ESI has been exhausted.
As envisaged by the EU Strategy for COVID-19 vaccines, the option of a top-up to the
ESI to cover any financing gap for additional contracts is available. In case an ESI top-up of
750 million Euro is agreed as outlined in the informal meeting we could further diversify the
portfolio and better hedge against risks. Please find attached an estimate of the budget impli-
cations based on the gross national income and assuming a minimum of seven vaccines in the
portfolio.
During the abovementioned meeting of EU Health Ministers a majority of you made a
concrete commitment to increase the ESI budget or indicated your willingness to contribute
financially, subject to national procedures. Your additional contributions to the ESI would
become external assigned revenue for the EU budget and they would be used for securing the
financing of further APAs.
Given the urgency, we look forward to receiving your reply on your commitment to
top-up the ESI by 15 September 2020 to EC Vaccines (
[email protected]). The time
has come to put words into action and gather the additional funding that could ensure that
additional promising vaccines are part of the EU portfolio to the benefit of all citizens in the
twenty-seven Member States of the European Union.
It is essential that we continue to coordinate and strengthen our efforts in a spirit of
solidarity, therefore let us remain united on the portfolio structure and together deliver a last-
ing and decisive solution to our citizens against COVID-19.
Yours sincerely,
STELLA KYRIAKIDES JENS SPAHN
MEMBER OF THE EUROPEAN COMMISSION FEDERAL MINISTER
HEALTH AND FOOD SAFETY MEMBER OF THE GERMAN PARLIAMENT
Enc.
Aili Petti
Teema: FW: ESI letter Bundesminister Jens Spahn und EU-Kommissarin Stella Kyriakides
Manused: Letter ESI_enc.pdf; Letter ESI.pdf
Tähtsus: Kõrge
From: Tairi Täht <
[email protected]>
Sent: Thursday, September 10, 2020 3:38 PM
To: Maris Jesse <
[email protected]>; Heli Laarmann <
[email protected]>; Elen Ohov <
[email protected]>;
[email protected]; Marten Kokk <
[email protected]>; Tanel Kiik <
[email protected]>; Triin Uusberg
<
[email protected]>
Cc: Katrin Juhandi <
[email protected]>; Kristiina Tuisk (Riigikantselei)
<
[email protected]>; Rasmus Sinivee <
[email protected]>
Subject: FW: ESI letter Bundesminister Jens Spahn und EU-Kommissarin Stella Kyriakides
Importance: High
Tere
Siin on PRES+KOM ühiskiri liikmesriikidele vaktsiini eelostulepinguteks vajaliku ESI top up teemal, mis saadeti ka
pealinnadesse. Meie nõusolekut anda oma lisapanus palutakse hiljemalt 15.09 (järgmine teisipäev). Sain eesistujast
aru, et see saab olema ainuke ametlikumas vormis dokument, mida meile esitatakse sel teemal. PRES viitab alla
meilis, et kõik info otsustamiseks (portfelli teemal) on olemas Steering Boardis.
Tervitades
Tairi
*** TÄHELEPANU *** See e-kiri (kaasa arvatud manused) on mõeldud ainult e-kirja adressaatidele ning võib sisaldada ametialaseks kasutamiseks ettenähtud teavet. Teavet ei tohi ilma saatja
selgelt väljendatud loata edasi saata ega mistahes viisil kõrvalistele isikutele avaldada. Juhul, kui Te olete saanud käesoleva e-kirja eksituse tõttu, palun teavitage sellest kohe saatjat ning
kustutage e-kiri oma arvutist.
*** ATTENTION *** This e-mail and its attachments may contain official information. If you are not the intended recipient, please notify the sender immediately, delete this e-mail and destroy any
copies. Any dissemination or use of this information by a person other than the intended recipient is unauthorized and may be unlawful .
From: Katharina Wunderlich <
[email protected]>
Sent: Thursday, September 10, 2020 12:23 PM
To:
[email protected]; Zlatimira Dobreva (
[email protected]) <Zlatimira.Dobreva@bg-
permrep.eu>;
[email protected]; Tairi Täht <
[email protected]>; Mustonen Pasi <
[email protected]>;
[email protected];
[email protected]; Aikaterini Damigou (a.damigou@rp-
grece.be) <
[email protected]>;
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected]; Ewa Magdalena Piasecka
(
[email protected]) <
[email protected]>;
[email protected]; João
Miguel Lança <
[email protected]>;
[email protected];
[email protected];
[email protected];
Teodor Zepic (
[email protected]) <
[email protected]>;
[email protected];
[email protected];
[email protected];
[email protected];
[email protected]
Cc:
[email protected];
[email protected]; '
[email protected]' <
[email protected]>;
'SVENSSON Lars Erik' <
[email protected]>; Aurélien Perez
(
[email protected]) <
[email protected]>; CZARNECKA Agnieszka
<
[email protected]>; Marie Charlotte van Lamsweerde (marie-
1
[email protected]) <
[email protected]>; DE
ELERA Alvaro <
[email protected]>
Subject: ESI letter Bundesminister Jens Spahn und EU-Kommissarin Stella Kyriakides
Importance: High
Dear colleagues,
please find attached the letter of Minister Spahn and Commissioner Kyriakides to your capitals regarding the ESI top
up to finance further APA contracts for COVID-19 vaccines.
And just to clarify the issue on the budget that was also raised by our budget colleagues: the transfer of ESI money
(around 1,1 billion Euro) from 2021 to 2020 (DAB No. 8) is needed to finance the current portfolio of 6 vaccines
candidates. The additional 750 million Euro is needed for possible extensions of the vaccine portfolio. The decision
which and how many additional vaccine candidates to take on board is decided by member states in the Vaccines
Steering Board.
Thank you for forwarding the letter to the responsible persons in your capitals as well.
Kind regards
Katharina
Katharina WUNDERLICH
Referentin Gesundheitspolitik
Ständige Vertretung
der Bundesrepublik Deutschland
bei der Europäischen Union
Rue Jacques de Lalaing 8-14, 1040 Brüssel
Telefon: +32 2 787 1303
Folgen Sie uns! @GermanyInTheEU:
Mobil: +32 476 762 116
E-Mail:
[email protected]
2